Gilead to unveil 28 HIV and antiviral research findings at IDWeek 2026
Gilead Sciences will present 28 research results at IDWeek 2026 in Washington, D.C., from October 21‑24, 2026. The data include Phase 3 analyses of Bixlenvo in patients with comorbidities, real‑world U.S. adoption of Yeztugo for PrEP covering June 2025‑March 2026, and final Phase 1b results for investigational GS‑1179 for genital herpes. Additional studies address rapid ART restart with Biktarvy and factors influencing PrEP access.
Why it matters
The presentations will provide investors with new efficacy, safety and adoption data that could affect future regulatory decisions and market perception of Gilead’s HIV portfolio. The disclosed real‑world uptake figures for Yeztugo may signal commercial traction for the twice‑yearly PrEP product.
Key facts
- 1Gilead will present 28 research findings at IDWeek 2026. investing.com
- 2IDWeek 2026 is scheduled for October 21‑24, 2026 in Washington, D.C. investing.com
- 3Bixlenvo is approved in the United States for HIV treatment but not outside the U.S. investing.com
- 4Yeztugo is approved in the United States, EU, Canada, Brazil, South Africa, Australia, Zambia and Zimbabwe for HIV prevention. investing.com
- 5GS‑1179 remains investigational. investing.com
- 6Real‑world adoption data for Yeztugo cover the period June 2025 through March 2026. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.